Navigation Links
Star Scientific, Inc. Refutes Story Published on

GLEN ALLEN, Va., Jan. 28, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) commented today on a January 23, 2013, column appearing on That piece contains numerous false and misleading statements regarding the Company's anatabine research and the initial results of the ASAP Human Thyroid Health Study released by Star Scientific on January 7, 2013.  

(Logo: )

As reported in the Company's January 7, 2013, press release: "The preliminary examination of the primary outcomes shows a clear and statistically significant difference in the treated group as compared to the placebo group by the end of the trial, with declines in anti-thyroglobulin antibody levels.  Anatabine subjects also tended toward a reduction in thyroid gland vascularity on ultrasound relative to placebo."

The ASAP study, which examines the impact of anatabine dietary supplementation on thyroid health, was conducted by Rock Creek Pharmaceuticals, the Company's subsidiary.  The study was not sponsored by the Johns Hopkins School of Medicine, and the Company never reported otherwise.  Indeed, when Star Scientific first announced IRB approval of this study on February 9, 2012, it noted that the study was being conducted by Rock Creek Pharmaceuticals at sites in Texas, Illinois, and Florida.  The Company also consistently referenced that this study was being conducted by Rock Creek Pharmaceuticals at multiple sites in subsequent press releases, including the January 7, 2013, release.  Any implication by the author of the article in that Star Scientific stated otherwise is patently false. 

The statement that there is no science backing that anatabine reduces inflammation similarly is completely false.  Since 2011, Rock Creek Pharmaceuticals and researchers at the Roskamp Institute have completed and reported on a number of studies designed to assess the ability of the Company's anatabine compound to lower chronic inflammation in a variety of pre-clinical (non-human) and clinical (human) settings. One study conducted by the Roskamp Institute and reported in The Journal of European Pharmacology in 2011 showed that anatabine lowered levels of amyloid production both in the test tube and when administered to mice vulnerable to accumulation of amyloid which, at excessive levels damages brain tissue.  A second manuscript written by the same researchers and published online in The Journal of European Pharmacology in 2012 and in manuscript form in January 2013 further characterized the anti-inflammatory effects of anatabine in several types of animal tissues, in human cells, and in human whole blood. The Roskamp Institute also presented results of pre-clinical studies of anatabine in mouse models of multiple sclerosis, traumatic brain injury, and Alzheimer's disease at the Neuroscience 2012 conference held in New Orleans in October 2012.

In January 2012, Rock Creek Pharmaceuticals reported research on the first clinical trial demonstrating that Anatabloc® lowers chronic inflammation measured by CRP levels in the blood. The reported results were obtained in connection with an in-house study undertaken by Rock Creek that involved a group of smokers who had been using Anatabloc® on an extended basis.  In October 2012, Rock Creek reported on an interim look at the CRP results in a study sponsored by the Roskamp Institute and designed to assess the safety, tolerability, dosing, and biological effects of anatabine citrate.  Currently, a clinical study of individuals with mild to moderate Alzheimer's disease is being sponsored by Rock Creek Pharmaceuticals and conducted at the Roskamp Institute.

Prior to the introduction of the Company's first dietary supplement, research scientists at Harvard University's McLean Hospital completed extensive research, which was funded by Rock Creek Pharmaceuticals, relating to the safety of anatabine as well as its non-nicotinic effects in connection with development of the product.

Furthermore, The article's implication or suggestion that Johns Hopkins has had no involvement in anatabine research is also false.  As previously reported, a preclinical investigator-initiated and independently funded study from Johns Hopkins examined the effect of anatabine supplementation on autoimmune thyroiditis in a mouse model and that research was recently published in an article entitled, "Anatabine Ameliorates Experimental Autoimmune Thyroiditis" in the Endocrine Society's journal, Endocrinology.  (Endocrinology. 2012 Sep; 153(9):4580-7.)  All three of the published articles referenced in this press release were peer reviewed anonymously by experts in the field chosen by the editors of the journals. 

Star Scientific notes that the author of the article in, Adam Feuerstein , has published a number of negative articles regarding the Company and its research on anatabine.  The Company believes that investors and consumers of its Anatabloc® product would be well advised to view any such articles by this author or publications regarding the Company in with substantial skepticism, given the misstatements and misinformation that the author disseminates. 

Star Scientific takes its responsibilities to provide and present accurate information about and to respond to false statements about its products very seriously.  This press release and communications that are being sent to The Street and its author by Star Scientific's attorneys are examples of that effort.

Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical products, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2011. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.

About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to promote maintenance of a healthy metabolism and lifestyle. Over the last several years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star Scientific has been engaged in the manufacturing, sale, and marketing of two nutraceutical dietary supplements, and the development of other nutraceuticals and pharmaceuticals. The company also continues to pursue the licensing of the technology behind its proprietary StarCured® curing process and its related products. Rock Creek Pharmaceuticals has scientific and research offices in Gloucester, MA, and a regulatory office in Washington, DC. Star Scientific has a Corporate and Sales Office in Glen Allen, VA, and an Executive, Scientific & Regulatory Affairs office in Washington, DC.

Talhia T. Tuck
Vice President, Communications and Investor Relations
Star Scientific, Inc.

SOURCE Star Scientific, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
2. Producer Austin Chapman Reaches Millions with Inspiring Story on Hearing Loss; Launches Contest in Partnership with Phonak
3. Shield HealthCare Announces 12th Annual Caregiver Story Contest
4. Medical Marijuana Inc.s Subsidiary, PhytoSPHERE Systems, Signs the Largest Production Contract in Company History Valued at $7.5 Million
5. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
6. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
7. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
8. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
9. Research Published in European Journal of Pharmacology Shows that Star Scientifics Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimers Disease and in Blood
10. Study Published in Otology & Neurotology Shows Benefits of Cochlear Implant Sound Processor with Dual-Microphone Technology
11. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
Post Your Comments:
(Date:10/12/2015)... 12, 2015  CME Group,s Center for Innovation ... of Theranos, is the 11 th recipient of the ... revolutionary blood diagnostics company, Theranos , to change health ... a new era of preventive care. CME Group will present ... Conference in Naples, Florida , on ...
(Date:10/12/2015)... 12, 2015 --> ... Review, H2 2015 market research report provides data ... by identifying new targets and MOAs to produce ... . --> . ... across 62 pages, analyzing 6 companies, 8 drug ...
(Date:10/12/2015)... October 12, 2015 --> ... on the global vital signs monitoring devices market in its ... Analysis and Opportunity Assessment 2015-2025." The global vital signs monitoring ... of 9.5% and 9.2% in terms of value and volume, ... FMI offers major insights in detail in this report. ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... Debbie Vereb has been named the organization’s Executive Vice President of Operations, and ... hired to key leadership roles in the company. , Debbie Vereb’s appointment to ...
(Date:10/13/2015)... ... 13, 2015 , ... Curly Hair Solutions® is thrilled to ... an exhibition featuring the newest products and services to hit the market for ... more excited to unveil their recent partnership with Trade Secrets, a leading Canadian ...
(Date:10/13/2015)... , ... October 13, 2015 ... ... LLC presented results from GyencoloGeneTM, the world’s first commercially-available next-generation sequencing laboratory ... FIGO World Congress of Gynecology and Obstetrics in Vancouver, BC, Canada. ...
(Date:10/13/2015)... NY (PRWEB) , ... October 13, 2015 , ... ... her award winning programs Elder Care Doula Training and End of Life ... elderly in a holistic model, physically, spiritually and emotionally. Based on her ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
Breaking Medicine News(10 mins):